The Biotech Hiring Market in 2026: Where Things Actually Stand

After a few years that tested the patience of just about everyone in life sciences, the biotech job market has entered 2026 in a more settled state. The frenetic hiring sprees of 2021 and 2022, followed by the equally frenetic layoffs of 2024 and 2025, have quietened down. There's less drama. Less whiplash.

Steadier, though, is a long way from healthy. If you're responsible for building teams in this sector right now, the landscape still has real complexity to it, and some of the structural issues that have been building for years haven't gone away just because the market has calmed down.

Here's where things actually stand.

‍

The Candidate Pool Looks Bigger Than It Is

On paper, there are more available candidates in biotech right now than there have been in years. The layoffs of 2024 and 2025 were significant. Biopharma layoffs rose 16% year-on-year in 2025, with an estimated 42,700 employees affected. That's a lot of experienced people back in the market.

The catch is that availability and fit are two different things. When you're hiring for a highly specific role, such as a process development scientist with mRNA platform experience or a regulatory affairs lead who's navigated EMA approval for a cell therapy, the depth of that pool shrinks quickly. The people who match those profiles are still scarce, and they're still being pursued by multiple organisations simultaneously.

This creates an odd dynamic where hiring managers feel like they should be spoilt for choice, and then find they aren't. It's worth being clear-eyed about this when setting expectations internally, especially with boards or leadership teams who assume the market downturn makes every hire an easy one.

‍

Candidate Confidence Has Taken a Hit, and That Has Consequences

One of the more striking data points from early 2026 is just how rattled biopharma professionals are. Over half of currently employed candidates are actively looking for something new, and among those out of work, 85% are weighing roles in other industries entirely. One survey respondent put it plainly: "There is zero job security in biopharma."

That kind of sentiment has real implications for how you recruit. Candidates who've been through layoffs, or watched colleagues go through them, are going to scrutinise your company's runway, pipeline stability, and leadership more carefully than they would have in a bull market. The pitch of "come join our exciting early-stage journey" doesn't land the same way it did in 2021.

Hiring managers need to be more forthcoming about financial position, strategy, and what genuine job security looks like at their organisation. The candidates worth hiring will ask. Being evasive or overly promotional in those conversations will cost you good people.

‍

The Skills Gap Is Getting Quietly Worse

Here's a problem that doesn't get enough attention: the talent pipeline is narrowing at the edges, and it's partly a consequence of the market contraction itself.

Reduced hiring means fewer people are moving between roles, taking on new responsibilities, or developing skills through on-the-job exposure. The cross-functional experience that tends to produce excellent senior candidates, the kind who can straddle scientific credibility and operational leadership, takes time to accumulate, and that accumulation has slowed.

Specialist areas are feeling this most acutely. Cell and gene therapy attracted $15.2 billion in investment in 2025, growing 30% on 2023 figures. That capital will translate into hiring demand, but the talent infrastructure to support it hasn't grown at the same pace. The same is true in bioinformatics and computational biology, where roles increasingly require a hybrid of deep domain science and data or programming skills that relatively few people have built over the course of a career.

The short-term response for many companies has been to compete harder for the same small group of people. The more sustainable answer involves rethinking how you develop talent internally and how much weight you place on adjacent experience versus exact-match credentials.

‍

The Office Question Still Isn't Settled

Biotech is more location-dependent than most industries. You can't run a cell culture from a home office, and the expectation of flexibility hasn't disappeared just because lab work requires physical presence.

Companies have pulled back substantially on remote hiring since the pandemic peak. The share of employers willing to recruit regardless of location dropped from nearly 50% in 2022 to around 20% in 2024. Most now prefer local candidates, with hybrid arrangements available for roles that don't require daily lab access.

The practical challenge for hiring managers is that rigid location requirements will exclude strong candidates, particularly for analytical, regulatory, and commercial roles where proximity to a lab isn't strictly necessary. It's worth being precise about which roles genuinely need on-site presence and which ones are defaulting to it out of habit or cultural preference. That distinction matters more than ever when you're trying to attract senior talent from outside your immediate geography.

‍

Retention Is the Underrated Priority

More organisations are investing in their existing people rather than replacing them. Given the cost of mis-hires at the senior level, and the reputational cost of being seen as a company that churns through staff, this makes obvious sense. It also reflects something more pragmatic: in a market where specialist talent is hard to find and expensive to attract, holding onto people who already understand your platform, your culture, and your stage of development is a genuine competitive advantage.

This means thinking seriously about development pathways, not just remuneration. Experienced biotech professionals who feel their growth has stalled will look elsewhere, and in the current climate, they have options, even if the market overall is tighter.

‍

What This Means for 2026

The biotech hiring market isn't broken, but it does require more strategic thinking than it did when capital was cheap and candidates were less wary. The organisations that will build the best teams over the next 12 to 18 months are the ones treating recruitment as a long-term function rather than a reactive one, mapping future talent needs against pipeline milestones, building relationships before vacancies open, and being honest with candidates about what they're joining.

At Vector Talent, this is the kind of nuanced market we spend our time thinking about. If you're navigating hiring decisions in biotech right now and want a clearer picture of what's actually available and what it will realistically take to secure it, we're always glad to have that conversation.